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A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The
availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with
defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in
human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for
educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and
shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery.
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Advances in our understanding of the molecular basis of cancer
initiation, progression and metastatic expansion have raised hopes
for quick translation of this new data for improved cancer
detection, classification, monitoring and especially treatment.
However, as pointed out by Varmus (2006), despite the significant
progress in several individual cancers and the recent annual 1%
decline in cancer-caused mortality rate in the United States, after
several decades of steady increases, there are still major obstacles
and challenges. The complexity of the problem is also manifested
by the low success rate (for 1991–2000) in oncology drugs entering
the clinical phase (5%), as compared with the 11% average rate of
success for all therapeutic areas (Kola and Landis, 2004).
Unfortunately, in terms of costs, the vast majority of drug attrition
in all disease areas is at late stages of clinical drug development
(phases II and III). In 2000, the major causes of attrition in the
clinic had been lack of sufficient efficacy (30%) and toxicity (30%)
pertaining to both off-target and on-target toxicity (Kola and
Landis, 2004).
Two recent reviews have dealt with the formidable problem of
identification of drugs with improved efficiency and cancer
selectivity (Benson et al, 2006; Collins and Workman, 2006). The
former review by a Novartis Corp. group defined four tracks of
cancer targets: genetics, synergy, lineage and host. These four
subtypes of cancer targets can be viewed as ‘dependencies’, which
constitute potential weaknesses – Achilles heels that are unique to
cancer cells and can thus be exploited for therapy. The synergy
track constitutes synthetic lethal genetic interactions.
The purpose of this minireview is to examine the methodologies
that dictate the experimental plans and progress, in application of
the concept of synthetic lethality for the identification of lead
compounds/drugs, and to a limited extent also of targets, for
cancer therapy. Noteworthy is the extensive review by Kaelin
(2005) on ‘The concept of synthetic lethality in the context of
anticancer therapy’, which presents the issue.
THE BASICS OF SYNTHETIC LETHALITY
Synthetic lethality describes a cellular condition in which two (or
more) non-allelic and non-essential mutations, which are not
lethal on their own, become deadly when present within the same
cell. The synthetic lethal mutations may constitute partial
mutations present together in a single linear essential pathway
(Figure 1A), reside in parallel pathways leading to the synthesis
of a common essential gene product (Figure 1B) or constitute
independent parallel survival pathways each serving as salvage
pathway in the absence of the other (see Figure 1C). Intermediate
situations in which two mutant genes may generate a ‘synthetic
sickness’ condition might also exist. These occurrences may
become lethal and lose viability when combined with one or more
additional non-essential mutation/s.
Although tentatively, the two mutant synthetic lethal genes are
presumed to represent loss-of-function mutations, a condition of
synthetic lethality between an overexpressed ‘gene of interest’ and
a mutant null gene should also be taken into account (see below)
and has been initially described in yeast as a ‘synthetic dosage
lethality’ phenotype (Kroll et al, 1996).
The first methodology for genetic synthetic lethality screen has
been initially developed in yeast, Saccharomyces cerevisiae (Bender
and Pringle, 1991). A wild-type copy of the ‘gene of interest’, on an
unstable episomal plasmid (containing an origin of DNA replica-
tion but no centromere), is introduced into yeast cells that are null
for expression of this gene. Random mutagenesis of the entire
yeast genome within these cells may inactivate a gene that is
synthetic lethal with deficiency in the gene of interest. Under these
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www.bjcancer.comconditions, retention of the episomal plasmid, which is otherwise
spontaneously lost, and expression of the gene of interest become
essential for survival. Plasmid loss or retention is detected by
changes in colony pigmentation. Identification of the mutagenised
synthetic lethal gene is accomplished by transforming the
particular colony cell population with a wild-type yeast genomic
library, while selecting for a change in pigment colour reflecting a
loss for the need of the episomal plasmid (i.e., loss of the synthetic
lethal condition). The availability of numerous yeast knockout
mutants, and the implied added advantage of the method in
revealing interactions that do not necessarily require physical
interaction between the two gene products, has quickly made this
method one of the most powerful in yeast genetics.
Two different modifications of the basic concept have created
genetic synthetic lethality screens that are less tedious, more
informative and thus suitable for genome-wide analysis. In one,
termed synthetic genetic array (SGA), double mutants are
generated by mating the query mutant haploid strain to a panel
of yeast knockout mutant strains; unviable double-mutant meiotic
progeny identifies synthetic lethal relationships (Tong and Boone,
2005). The alternative method named dSLAM for diploid-based
Synthetic Lethality Analyzed by Microarray (Pan et al, 2004) takes
advantage of TAGs representing DNA bar codes, which uniquely
mark each yeast deletion allele. These TAGs are flanked by shared
priming sequences for PCR. The query mutation is introduced into
a pool of heterozygote diploid knockout yeast strains by
integrative transformation. Following sporulation, the haploid
single (mock transfection)- and double-mutant populations are
selected. The presence of every individual deletion mutant within
any of the two pools is assayed by measuring the relative
abundance of its corresponding TAG-containing PCR product in
genomic DNA prepared from each one of the pools, and
competitively hybridising to a TAG oligonucleotide microarray.
The disappearance of a particular TAG from the double-mutant
cell population then may point to a synthetic lethal interaction.
The addition of the SGA and dSLAM versions of the yeast genetic
synthetic lethality screening enables identification of gene net-
works and cellular pathways that ‘buffer’ each other biologically
(Ooi et al, 2006).
The first to suggest the usage of synthetic lethality screening,
chemical as well as of genetic, for the development of cancer
therapy have been Hartwell and Friend (Hartwell et al, 1997).
However, figuring that the state of genetic manipulations in
mammalian and human-cell systems, in particular, was not ripe yet
for genome-wide genetic synthetic lethality screening (a situation
that has changed dramatically with the introduction of synthetic
siRNAs in 2001), they suggested the use of model genetic systems,
such as yeast, the nematode Caenorhabditis elegans and the
Drosophila melanogaster fruit fly.
CHEMICAL SYNTHETIC LETHALITY SCREENING IN
YEAST
In their search for cancer-specific genetic changes, which could
form potential selective therapeutic targets, Hartwell and Friend
relied on the fact that one of the hallmarks of cancer is genetic
instability. This instability is primarily caused by defects in DNA
repair, in cell cycle checkpoints and in other cell cycle controls.
Moreover, because these processes have been well conserved
between yeast and humans, these investigators used a panel
of up to 70 isogenic strains, each defective in either DNA repair or
cell cycle control gene/genes, for the systematic testing of the 33
most common FDA-approved anticancer cytotoxic drugs (Hartwell
et al, 1997; Simon et al, 2000). This screen identified targets which
sensitise chemotherapy drugs administered to yeast. The bifunc-
tional alkylating agent cisplatin, for example, was killing 100-fold
better (IC50 decreased by two logs) in the presence of defects in
either the Rad6 or Rad18 post-replication repair genes. Similarly,
defects in the Rad50, Rad51 or Rad52 double-strand break repair
through homologous recombination (HR) augmented by almost
two logs the killing efficiency by topoisomerase inhibitors, such as
camptothecin (Topo I) and mitoxantrone (Topo II). Obviously,
these chemotherapeutic-sensitising links call to be tested with
regard to their human orthologues in normal and tumour-derived
cell lines.
Also screened were more than 85000 compounds from the
collection of the Developmental Therapeutics Program (DTP)
branch of NCI (Dunstan et al, 2002). This large-scale chemical
screen (which was part of the Seattle project based at the Fred
Hutchinson Cancer Research Center) identified 126 compounds
that were selectively toxic to yeast cells defective in double-strand
break repair (rad 50/52 specific). Out of these, 87 compounds
were known or closely related to known topoisomerase inhibitors,
and 39 were of no known function. The manuscript relating to
this screen (Dunstan et al, 2002) described the analysis of eight
such compounds. The rest of the information (updated to 2002)
was made available at the DTP website http://www.dtp.nci.
nih.gov/yacds/index.html under ‘NCI Yeast Anticancer Drug
Screen’. Among the eight compounds analysed, seven were toxic
to mammalian cells; five classified as topoisomerase I poisons
and two as topoisomerase II inhibitors. This feasibility/proof-
of-concept study showed, in part, the pros and cons in using
a model organism for the identification of anticancer drugs in
humans.
A boost to the usage of chemical synthetic lethality screens in
yeast has been achieved by integrating drug-sensitivity profiles
with those of the large-scale genetic interaction data obtained
through genome-wide genetic synthetic lethality screens per-
formed by either SGA (Tong and Boone, 2005) or dSLAM (Pan
et al, 2004; Ooi et al, 2006). The clustering of the two profiles links
compounds to their protein targets and/or target pathways
(Parsons et al, 2004; Lopez et al, 2008).
Recently, the screening of chemical libraries in panels of
knockout collections of S. cerevisiae, for unravelling chemical
synthetic lethality relationships, has been complemented through
usage of collections of mutant yeast strains generated by meiotic
recombination (Perlstein et al, 2006).
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Figure 1 (A) Partial ablation of two enzymes located on one essential
pathway. (B) Ablation of two enzymes located on parallel pathways leading
to a common essential product. (C) Ablation of two enzymes on
independent survival pathways leading to synthetic lethality. Three modes
of cell survival pathways amenable for analysis by the synthetic lethality
screening approach.
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Methodology: high-throughput chemical screening
Over the past decade, three general methods of mammalian-cell-
based HTS for synthetic lethal compounds have been reported. The
first is the classical screening for genotype-specific inhibitors that
are differentially toxic to mutant cell lines grown in multiwell
plates. For example, the group led by Stuart Schreiber has screened
marine sponge extracts for replication inhibitory activity specific
for mouse embryo fibroblasts with either p53
/ or p21
kipl/
genotype vs wild type. The assay monitored BrdU incorporation by
cytoblotting (Stockwell et al, 1999). This classical differential
toxicity screening method is subject to several well-known
disadvantages: errors due to differences in cell density relating to
variations in cell-plating efficiency or growth rate; mistakes
resulting from differences in microenvironment growth conditions
among plates and wells (particularly regarding circumference
effects); the inability of most cell viability assays for multiple
readings from zero time on; and the high costs of tissue culture
ware and time required for growth analysis. Two methods were
independently developed to circumvent some of these short-
comings. In one, developed by Kinzler and co-workers (Torrance
et al, 2001), two isogenic human colon cancer cell lines, each
marked by a distinct mutant GFP gene, were co-cultured into the
same wells in multiwell plates. The two isogenic cell lines differed
in that in one the mutant K-Ras oncogene allele was deleted by HR
to generate a null allele. The co-culturing of the two isogenic cell
lines supplied a highly important internal control and created an
‘even growth environment’ that minimised potential differences in
cell density. The tagging of each cell line by a distinct GFP mutant
(capable of double-label reading) allowed for multiple time-point
assessments of the relative cell viability through GFP fluorescence
monitoring. Yet, this method still has two cell lines that may have
different growth rates and the co-culturing of which might render
one sensitive to growth-enhancing/inhibitory paracrine signals
secreted by the other.
The second recently developed method for high-throughput
chemical (and genetic) synthetic lethality screening was generated
for human cells (Simons et al, 2001a) and for mouse embryo
fibroblasts (Einav et al, 2003), by my research group. In trying
to establish a direct method for finding bona fide synthetic
lethality relationships between a chemical and a mutated gene
(or between two mutated genes in the genetic screen), we resorted
to the concept of the original equivalent yeast method, that is,
complementation expression of a gene of interest through a low-
copy-number unstable episomal replication, in which retention of
the episome is forced either by a selectable marker or by synthetic
lethal pairing with another gene. Under such synthetic lethal
conditions, retention of the episomal plasmid, expressing the wild-
type gene of interest, becomes indispensable for viability. Tagging
of the chromosomal host DNA and the episomal ‘survival plasmid’
with different GFP variants compatible for double-label fluores-
cence reading allows for the normalised quantitative detection of
the episomal plasmid. Microtitre plates were seeded with either
HPRT1-deficient human HT1080 fibrosarcoma cells or HPRT1 null
mouse embryo fibroblasts as model systems. We have then shown
using HPRT1-expressing Epstein–Barr Virus-based plasmid
replicons that one can screen and detect synthetic lethal chemicals
(Simons et al, 2001a; Einav et al, 2003) as well as genes (Simons
et al, 2001b; Einav et al, 2005). This purine biosynthesis de novo
and salvage pathways leading to the synthesis of the common
essential product GMP are an example for the model shown in
Figure 1B. The major advantage of this system is that it utilises a
single cell line that is thus immune to variations in cell growth
characteristics of isogenic cell line pairs or their putative paracrine
interactions with each other within the same well. Also, the assay’s
direct proof for a synthetic lethality condition (i.e. retention of the
‘survival plasmid’) spares a lot of controls needed when using the
two other methods that are based on the principle of differential
toxicity. On the basis of our experience, it is worthy to note that
usage of the GFP variant ratio tends to distort results somewhat.
At the same time, other viability detection methods, such as
respiration rates or ATP pools, may also harbour the disadvantage
of non-linearity, particularly in response to increased cell density.
It is for this reason that all HTS methodologies need to be well
calibrated to ensure linear responsiveness towards all system
parameters. Usage of unstable GFPs that have higher turnover
rates may potentially improve matters. Yet, in our model system,
the expression level of a GFP variant with a half-life time of 4h was
too low for accurate monitoring. Also, while attempting to use
episomal systems established in either breast carcinoma-derived
cell lines or MEFs, for screening chemical libraries containing very
large numbers (thousands) of chemicals, we observed loss of
episomes. This is to say that continuous large-scale cell propaga-
tion may lead to the loss of the episome, despite selection for a
dominant selectable marker gene encoded by the episome.
Concomitantly, there is an increased rate of integration into the
host chromosome, supporting resistance to the selectable marker.
In lieu of the above, the use of the episomal system should be
restricted to validation experiments or small-scale experiments in
which the episome containing transfectant cell line is limited to a
low passage number following its generation.
Screening for chemicals synthetic lethal with activated
oncogenes
Starting from an isogenic pair of mouse mammary epithelial cell
lines, one of which is stably expressing an ectopic neu/Her2
oncogene, Leder and co-workers screened a chemical library
containing 16000 compounds. One molecule, F16, a low-
molecular-weight delocalised lipophilic cation, preferentially
accumulated in the inner mitochondrial matrix due to its elevated
membrane potential (Dcm) (Fantin et al, 2002). This accumulation
led to the perturbation of mitochondrial homoeostasis and
eventual preferential cell death of the neu-overexpressing cells.
Further study has shown a linkage between F16 activity and
transformed cells displaying increased mitochondrial membrane
potential, rather than neu overexpression per se. In terms of its
potential cancer therapy usage, F16 is still at the discovery stage
(Fantin and Leder, 2006).
Another HTS of chemical libraries centred on tumour cells
overexpressing the Ras oncogene. Using their human colon cancer
isogenic cell lines in which a mutant K-Ras allele has been deleted
by targeted HR in one of the two cell lines (see above), the groups
led by Kinzler and Vogelstein have screened some 30000 low-
molecular-weight compounds (Torrance et al, 2001). Several
compounds with up to six-fold greater toxicity towards the K-
Ras-expressing cell line/s were identified. The cytidine nucleoside
analogue was among the compounds showing activity in xenograft
mouse models in vivo. Stockwell’s group has performed two
carefully designed large-scale differential toxicity screens for
chemicals synthetic lethal with oncogenic Ras expressed in human
cancer cells. A cell system, engineered by Weinberg’s group, in
which primary human forskin fibroblasts (BJ cells) were made
immortal, transformed and tumourigenic by the constitutive
expression of hTERT, SV40 large and small T oncogenes, and
activated Ras
V12 was used. Initially, 23550 compounds and later
47725 chemicals were screened for H-RAS/K-RAS-dependent
synthetic lethality (Dolma et al, 2003; Yang and Stockwell, 2008,
respectively). The first screen identified several known chemicals,
as well as a novel compound named erastin, for ‘eradicator of RAS
and Small T-expressing cells’, which displayed a modest eight-fold
tumour selectivity in this in vitro model cell system, while causing
a non-apoptotic cell death.
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compounds, named RSL5 and RSL3, for ‘oncogenic-RAS-selective/
lethal compounds’. These cause, like erastin, a non-apoptotic,
MEK-dependent and iron-dependent oxidative cell death. It is
worth noting that cells transformed by oncogenic RAS have an
increased iron content relative to their normal counterparts. Both
RSL5 and erastin target VDAC3, a voltage-dependent anion
channel 3. Interestingly, RSL3, whose mechanism of action is not
clear yet, has been tested on the NCI60 panel of human tumour
cell lines, and is found to have a unique sensitivity/resistance
profile, as defined by the COMPARE algorithm, relative to the
thousands of compounds already tested at NCI (Yang and
Stockwell, 2008).
Synthetic lethality with tumour suppressor gene deficiency
The screening for chemicals synthetic lethal with a tumour
suppressor gene deficiency, in isogenic pairs of tumour cell lines,
poses a particular problem for the reference/control cell line. The
generation of control ‘tumour suppressor gene-corrected cell line’,
by restoring the normal function of an aberrant destabilised
tumour suppressor protein with a stabilising ligand, is rarely
possible (see the case for the p53 tumour suppressor by Boeckler
et al, 2008). On the other hand, ectopic expression of the wild-type
gene in the tumour suppressor-deficient cell line usually leads
to cell cycle arrest and/or cell death (see below for the von Hippel-
Lindau (VHL) gene exception). Thus, researchers resorted to the
usage of either reconstructed human model systems (such as BJ
cells based) or intermediate-stage tumour cells, whose tumour
suppressor gene/s product/s can be sequestered by siRNA/shRNA,
or tumour suppressor-binding oncogenic proteins (SV40 large T
antigen, HPV E6/E7, etc.). Alternatively, investigators have chosen
to design their experimental screening systems based on under-
standing the consequences of particular tumour suppressor gene
deficiency.
The case for VHL The VHL tumour suppressor gene is inacti-
vated in about 75% of clear-cell renal cell carcinoma (CC-RCC)
patients. Screening for chemicals or downregulated genes synthetic
lethal with VHL inactivation was made possible by the observation
by Kaelin’s group that unlike most human tumour suppressor
genes ectopic expression of VHL does not lead to inhibition of cell
growth or of cell-cycle distribution in vitro, but rather to
suppressing tumour formation in nude mice xenografts (Iliopoulos
et al, 1995). One function of VHL is as an E3 ubiquitin ligase,
which targets the hypoxia-inducible factor a (HIF-a) transcription
factor for oxygen-dependent proteolysis. Using in silico analysis of
existing publicly available drug profiles of the NCI60 cell lines,
chromomycin A3 (ChA3) was identified as being potentially lethal
with VHL deficiency in CC-RCC. This HIF-dependent inhibition
was first confirmed in vitro, followed by in vivo mouse xenograft
validations (Sutphin et al, 2007). The same group (of Amato
Giaccia) then screened a 64000 compound library against
VHL-deficient vs VHL-complemented RCC cells to identify the
STF-62247 as a chemical synthetic lethal with VHL deficiency
in vitro (25-fold difference in IC50), as well as in vivo. Unlike
ChA3, STF-62247 cytotoxicity is HIF independent and engages
autophagy induction (Turcotte et al, 2008). VHL deficiency and its
synergistic lethal inhibitors represent examples of the model
shown in Figure 1A.
The case for PTEN The PTEN (phosphatase and tensin homologue
deleted on chromosome 10) tumour suppressor gene is the second
most frequently mutated tumour suppressor gene after p53. PTEN
antagonises the PI3K/AKT signal transduction pathway by dephos-
phorylating the PIP3 second messenger, which itself is formed from
PIP2 by PI3K-dependent phosphorylation. In the absence of PTEN,
AKT is activated by its recruitment to the cell membrane through its
ligand – PIP3. The AKT kinase has many downstream substrates
involved in apoptosis, cell proliferation and protein synthesis, one of
which is mTOR (mammalian target of rapamycin). The synthetic
lethality relationship between PTEN deficiency and mTOR-over-
expression inhibition was discovered by showing an enhanced
sensitivity of PTEN-deficient tumours to the mTOR inhibitor CCI-
779, a rapamycin homologue (Neshat et al, 2001; Podsypanina et al,
2001). Thus, the search for PI3K/AKT/mTOR inhibitors that are
synthetic lethal, with PTEN deficiency in particular tumours, was
intensified (see recent review by Yap et al, 2008). In a comple-
mentary elegant approach, the group led by Pamela Silver decided
to try restoring at least some of the outcomes of PTEN function as a
tumour suppressor gene by screening a renal carcinoma cell line
(that is deficient in PTEN) for chemicals that relocalise the FOXOla
transcription factor to the nucleus (Kau et al, 2003). AKT is a
negative regulator of FOXOla. In PTEN null cells, AKT is activated
and phosphorylates FOXOla, which is thus mislocalised to the
cytoplasm, where it is unable to inhibit cell cycle progression.
However, FOXOla is still capable of shuttling between the cytoplasm
and the nucleus. Using a FLAG tagging for ectopic FOXOla
expressed in the host PTEN-deficient tumour cells and an
immunostaining-imaging assay, 18000 compounds were screened
for imposing FOXOla nuclear retention. Forty-two lead compounds
were identified, about half of which worked as general nuclear
export inhibitors by targeting the CRM1 export transporter. Most of
the other chemicals inhibited PI3K/AKT signalling. A large part of
these 42 inhibitors blocked cell proliferation in a short-term assay
(Kau et al, 2003).
The case for BRCA1/BRCA2 Our DNA is continually damaged by
either endogenous activities, such as DNA replication and cellular
free-radical generation, or exposure to environmental agents. This
leads to diverse lesions, such as double- or single-strand breaks
(DSBs and SSBs, respectively), base modifications and intrastrand
or interstrand cross-links. Double-strand breaks are considered to
be the most toxic of all DNA lesions. In mammalian cells, DSBs are
generally repaired by non-homologous end-joining during G0,G 1
and early S phases of the cell cycle, and by HR during the S–G2
phases of the cell cycle. The BRCA1 and BRCA2 human tumour
suppressor genes are deficient in a subset of breast, ovarian and
prostate cancers, and are normally required (among their other
roles) for DSB repair by HR. The most common spontaneous DNA
lesion in humans is base damage (B10000 lesions per cell per
day). Base excision repair (BER) is the major repair pathway for
this lesion, with poly-(ADP) ribose polymerase 1 (PARP-1) enzyme
being one of its essential repair ingredients. Inhibition of PARP-1
activity leads to persistence of SSBs (common intermediates in
BER), which once encountered (in S phase) by a DNA-replication
fork would result in fork stalling and potential DSBs. The
formation of the latter can be repaired by HR. However, if
impaired by BRCA1 or BRCA2 loss could result in cell cycle arrest
and/or cell death. This potential synthetic lethal condition was
tested and verified by the groups of Thomas Helleday and
Alan Ashworth, while using PARP-1 inhibitors and BRCA1- or
BRCA2-deficient cells (Bryant et al, 2005; Farmer et al, 2005). In
view of recent discoveries of additional roles for PARP-1 in DNA
repair, besides BER, the suggested mechanism for the synthetic
lethality between PARP-1 inhibitors and BRCA1/BRCA2 defi-
ciency, based on PARP-1-dependent ablation of BER, is but one of
the several potential explanations (see Helleday et al, 2008; Lord
et al, 2008). The homozygote BRCA1- or BRCA2-deficient cells
were found to be 100- to 1000-fold more sensitive to PARP-1
inhibitors than the wild-type or heterozygote cell lines. The latter is
particularly important, as normal, non-tumour cells in patients
bearing BRCA1/BRCA2 mutations are heterozygotes. This mono-
therapy approach has a potentially large therapeutic window, with
higher specificity and less side effects than standard cytotoxic
chemotherapy.
Synthetic lethality screening in anticancer therapy
D Canaani
1216
British Journal of Cancer (2009) 100(8), 1213–1218 & 2009 Cancer Research UKThe proven synthetic lethality between deficiencies in the
HR-dependent DNA repair genes, BRCA1 or BRCA2, and PARP-
1 inhibition has opened up several directions of clinical trials.
Several PARP-1 inhibitors are currently in phase I or II of clinical
monotherapy trials in BRCA1/BRCA2-deficient breast or ovarian
cancers (Helleday et al, 2008; Lord and Ashworth, 2008).
To augment the DNA-damage burden (on top of the sponta-
neous DNA damage), which cannot be repaired due to PARP-1
inhibition and deficiency in HR repair (BRCA1/BRCA2 deficiency),
combination therapies are designed in which effective chemo-
therapeutics affecting DNA integrity are added together with
PARP-1 inhibitors; this is a good example for the model shown in
Figure 1C, in which the outcome is DNA integrity affecting cell
survival. Accordingly, early clinical trials are underway in which
either one of the alkylating agents temozolomide, carboplatin,
mitomycin or other DNA-damaging agents are added in combina-
tion with a PARP-1 inhibitor to patients with mutant BRCA1/
BRCA2 tumours (see details in Helleday et al, 2008 ; Lord and
Ashworth, 2008). Also, in view of the fact that a fraction of the
triple-negative (ERa
,P R
, HER2
) breast carcinomas display
BRCA1/BRCA2 deficiency, phase-II clinical trials of this patient
group, with PARP-1 inhibitors on their own or together with
effective chemotherapeutics, are ongoing (http://clinicaltrials.gov).
CONCLUSION
The hopes for generating selective cancer drugs by virtue of their
synthetic lethal interactions with tumour-specific aberrations are
only beginning to materialise. It seems that early efforts in which
model organisms, and yeast in particular, were used for drug
discovery, have contributed primarily to methodologies, helping
shape our experimental approaches in mammalian systems further
on. Seemingly, the ‘hit’ rate in large-scale chemical synthetic
lethality screening for anticancer compounds in mammalian
systems turned out variable and low, requiring large resources of
chemical libraries and automated screening facilities. The greater
usage in the academia of HTS centres (such as those supported by
the Molecular Libraries and Imaging Initiative and the Initiative
for Chemical Genetics) and databases (such as PubChem and
ChemBank) should certainly improve the prospects of finding new
drug candidates.
The concept of searching for cancer drugs through synthetic
lethality seems to be more rewarding when either the assay
(FOXO1a in PTEN
/) or the potential target gene (mTOR in
PTEN
/) can be decided upon based on data mining and prior
knowledge of the normal and tumourigenic biological system. The
most advanced case is the PARP-1 inhibitors, on their own or in
combination with DNA-damaging chemotherapeutics, which are in
phase-II clinical trials with breast/ovarian cancer patients having
BRCA1/BRCA2 null tumours. Yet, it should be recalled that PARP-
1-inhibitory drugs were readily available since their usage in the
nineties as chemosensitisers.
Although the identification of synthetic lethal lead compounds
through large-scale chemical screening may be hard to come by
because of chemical scarcity and large diversity, genetic synthetic
lethality screening for gene target identification through siRNAs
(Iorns et al, 2007) or constitutive/inducible shRNA libraries
(Ngo et al, 2006; Schlabach et al, 2008, respectively) seems more
promising. This is due, in part, to the limited number of human
genes, and the increased efficiencies of the RNAi tools. The
inclusion, on top of the above, of RNAi screens for sensitisers of
cancer drugs (Whitehurst et al, 2007), and initiatives such as the
‘Connectivity Map’, should further boost cancer targets and drug
identification/validation.
At the same time, it may eventually turn out that the number of
synthetic lethal interactions in human tumours/tumour cells is
relatively limited, because of cell heterogeneity within tumours and
multiplicity of compensatory survival pathways/subpathways,
respectively. In this context, because resistance to therapy in
many tumours may reside within cancer stem cells/tumour-
initiating cells (CSCs/TICs), it will be extremely important to
isolate CSCs and perform chemical and genetic synthetic lethality
screens within this pure population so that CSC-specific drugs and
targets could be identified.
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